Evidence map›Paper›PMID 42455315›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Predicting tumour and organ dose in α-radiopharmaceutical therapy: a

Robin I J Merkx, Simone C Kleinendorst, Mark Rijpkema, Gerben M Franssen, Alfred Morgenstern, Frank Bruchertseifer, Michael P Wheatcroft, Egbert Oosterwijk, Peter F A Mulders, Mark Konijnenberg and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Robin I J MerkxDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, Nijmegen, 6525 GA, The Netherlands.
Simone C KleinendorstDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, Nijmegen, 6525 GA, The Netherlands.
Mark RijpkemaDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, Nijmegen, 6525 GA, The Netherlands.
Gerben M FranssenDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, Nijmegen, 6525 GA, The Netherlands.
Alfred MorgensternJoint Research Centre, European Commission, Karlsruhe, Germany.
Frank BruchertseiferJoint Research Centre, European Commission, Karlsruhe, Germany.
Michael P WheatcroftTelix Pharmaceuticals Limited, Melbourne, Australia.
Egbert OosterwijkDepartment of Urology, Radboudumc, Nijmegen, The Netherlands.
Peter F A MuldersDepartment of Urology, Radboudumc, Nijmegen, The Netherlands.
Mark KonijnenbergDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, Nijmegen, 6525 GA, The Netherlands.
Sandra HeskampDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, Nijmegen, 6525 GA, The Netherlands. Sandra.Heskamp@radboudumc.nl.ORCID http://orcid.org/0000-0001-7250-0846

Funding

KWF Kankerbestrijding 2019-2, 12567Nederlandse Organisatie voor Wetenschappelijk Onderzoek 09150172010054Telix Pharmaceuticals Ltd. Telix Pharmaceuticals Ltd.
6 · The paper itself

Abstract

The aim of this study was to assess whether zirconium-89 (

methodsBALB/c nude mice bearing subcutaneous SK-RC-52 tumours were injected intravenously with 25-50 kBq

resultsThe biodistribution profile of the theranostic pair

conclusionThis study highlights variability in the predictive accuracy of the

Indexed as

ActiniumAlpha ParticlesRadiation DosageRadioisotopesRadiopharmaceuticalsZirconiumAnimalsAntibodies, MonoclonalCell Line, TumorFemaleHumansMiceMice, Inbred BALB CMice, NudeRadiometryTissue DistributionActiniumActinium-225Antibodies, MonoclonalG250 monoclonal antibodyRadioisotopesRadiopharmaceuticalsZirconiumZirconium-89Actinium-225DosimetryRadiopharmaceutical therapyRCCZr89

Identifiers

PMID42455315
PMCPMC13633313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.